|
KRAS Mutation Analysis in Colorectal Cancer
Genzyme’s KRAS Mutation Analysis provides additional guidance in therapeutic treatment decisions for patients with colorectal cancer (CRC).
Mutations in the KRAS gene, a known downstream signaling molecule in the EGFR signaling pathway, have been described in approximately 30-60% of colorectal carcinomas.
Recent studies have found mutations in the KRAS gene to be associated with a poor prognosis. Studies have also found KRAS mutations more frequent in patients who show limited clinical response to targeted anti-epidermal growth factor receptor (anti-EGFR) therapies. As a result, determining the KRAS mutational status of a tumor may guide therapeutic decision making for patients with CRC.
The molecular diagnostic procedure incorporates allele-specific primer extensions for detecting mutations in codons 12 and 13 of the KRAS gene.
CPT Codes:
83890, 83892(2), 83898, 83904(2), 83907, 83909(2), 83912
Please Note: Include a copy of the original pathology report.
Specimen Requirements:
Colorectal Tumor Specimens* (and metastases)
1. Formalin-fixed, Paraffin-embedded Block with Corresponding H&E (preferred specimen type):
- Tissues should be well-fixed in formalin. If an alternative fixative is used, it should be noted on the requisition.
- Store specimen at room temperature (20-23.5°C).
- Use cold pack for transport. Be sure cold pack is not in direct contact with specimen during transport.
2. Unstained Slides:
- Send all slides within 5-7 days of cutting.
- Minimum of 4 slides (w/ 1 H&E) or 5 slides (w/o H&E).
- Pre-cut slides from paraffin block in 7 micron sections.
- Air dry. Do not oven dry.
- Store specimen at room temperature (20-23.5°C).
3. Fresh Snap Frozen Biopsy:
- Fresh tissue snap frozen at -20°C.
- Store at -20°C.
- Ship on minimum of 10 lbs. dry ice.
* We will accept core needle biopsies, FNAs and pleural effusions; however, the smaller amount of tissue usually present in these specimens can lower the success rate of the assay.
Turnaround Time:
8-10 days
|